Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stebbins

Showing results (1021-1030 of 1,116) with videos related to

Pageof 112
Sort By:
Nature Communications|June 29, 2019
Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosisChristopher S Lunde, Erin E Stebbins, Rajiv S Jumani, et al.
Molecular Cancer Therapeutics|April 18, 2009
Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteinsJun Wei, Shinichi Kitada, Michele F Rega, et al.
European Journal of Heart Failure|March 3, 2022
Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fractionClara Saldarriaga, Dan Atar, Amanda Stebbins, et al.
JACC. Heart Failure|February 16, 2024
Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection FractionRobert J Mentz, Amanda Stebbins, Javed Butler, et al.
JAMA Cardiology|July 10, 2024
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical TrialCatherine P Benziger, Amanda Stebbins, Lisa M Wruck, et al.
Circulation|October 12, 2000
Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III TrialE J Topol, E M Ohman, P W Armstrong, et al.
American Heart Journal|June 2, 2020
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular eventsHarvey D White, Ralph A H Stewart, Anthony J Dalby, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2009
Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lungKarin J Stebbins, Alex R Broadhead, Christopher S Baccei, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2011
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicityRupesh Dash, Belal Azab, Bridget A Quinn, et al.
Experimental Cell Research|April 8, 2006
Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formationAaron N Nguyen, Elizabeth G Stebbins, Margaret Henson, et al.
Pageof 112

Showing results (1021-1030 of 1,116) with videos related to

Sort By:
Pageof 112
Nature Communications|June 29, 2019
Identification of a potent benzoxaborole drug candidate for treating cryptosporidiosisChristopher S Lunde, Erin E Stebbins, Rajiv S Jumani, et al.
Molecular Cancer Therapeutics|April 18, 2009
Apogossypol derivatives as antagonists of antiapoptotic Bcl-2 family proteinsJun Wei, Shinichi Kitada, Michele F Rega, et al.
European Journal of Heart Failure|March 3, 2022
Vericiguat in patients with coronary artery disease and heart failure with reduced ejection fractionClara Saldarriaga, Dan Atar, Amanda Stebbins, et al.
JACC. Heart Failure|February 16, 2024
Recurrent Hospitalizations and Response to Vericiguat in Heart Failure and Reduced Ejection FractionRobert J Mentz, Amanda Stebbins, Javed Butler, et al.
JAMA Cardiology|July 10, 2024
Aspirin Dosing for Secondary Prevention of Atherosclerotic Cardiovascular Disease in Male and Female Patients: A Secondary Analysis of the ADAPTABLE Randomized Clinical TrialCatherine P Benziger, Amanda Stebbins, Lisa M Wruck, et al.
Circulation|October 12, 2000
Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction: results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III TrialE J Topol, E M Ohman, P W Armstrong, et al.
American Heart Journal|June 2, 2020
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c < 7% are associated with lower major cardiovascular eventsHarvey D White, Ralph A H Stewart, Anthony J Dalby, et al.
The Journal of Pharmacology and Experimental Therapeutics|December 10, 2009
Pharmacological blockade of the DP2 receptor inhibits cigarette smoke-induced inflammation, mucus cell metaplasia, and epithelial hyperplasia in the mouse lungKarin J Stebbins, Alex R Broadhead, Christopher S Baccei, et al.
Proceedings of the National Academy of Sciences of the United States of America|May 11, 2011
Apogossypol derivative BI-97C1 (Sabutoclax) targeting Mcl-1 sensitizes prostate cancer cells to mda-7/IL-24-mediated toxicityRupesh Dash, Belal Azab, Bridget A Quinn, et al.
Experimental Cell Research|April 8, 2006
Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formationAaron N Nguyen, Elizabeth G Stebbins, Margaret Henson, et al.
Pageof 112